Veradermics Hair Loss Data And Funding Reignite Interest In MANE Stock

Simply Wall St.05-14 14:47

Veradermics (NYSE:MANE) reported positive Phase 2/3 topline results for its oral pattern hair loss candidate VDPHL01, positioning it as a potential first new FDA-approved oral option in this category ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635799146?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-05-14 14:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635799146","market":"nz","top_or_hot":-1,"title":"Veradermics Hair Loss Data And Funding Reignite Interest In MANE Stock","media":"Simply Wall St.","content":"<div>\n<p>Veradermics (NYSE:MANE) reported positive Phase 2/3 topline results for its oral pattern hair loss candidate VDPHL01, positioning it as a potential first new FDA-approved oral option in this category ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mane/veradermics/news/veradermics-hair-loss-data-and-funding-reignite-interest-in\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Veradermics Hair Loss Data And Funding Reignite Interest In MANE Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVeradermics Hair Loss Data And Funding Reignite Interest In MANE Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-14 14:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mane/veradermics/news/veradermics-hair-loss-data-and-funding-reignite-interest-in><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Veradermics (NYSE:MANE) reported positive Phase 2/3 topline results for its oral pattern hair loss candidate VDPHL01, positioning it as a potential first new FDA-approved oral option in this category ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mane/veradermics/news/veradermics-hair-loss-data-and-funding-reignite-interest-in\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MANE","symbol_name":"Veradermics, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mane/veradermics/news/veradermics-hair-loss-data-and-funding-reignite-interest-in","article_id":"2635799146","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mane/veradermics/news/veradermics-hair-loss-data-and-funding-reignite-interest-in","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2635799146","pubTimestamp":1778741222,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Veradermics (NYSE:MANE) reported positive Phase 2/3 topline results for its oral pattern hair loss candidate VDPHL01, positioning it as a potential first new FDA-approved oral option in this category in almost 30 years.\nThe company also highlighted completion of enrollment in other key clinical studies and recent substantial funding to support ongoing programs.\nThe stock last closed at $107.14, with a 30 day return of 50.1% and a year to date return of 183.8%.\n\nFor investors watching...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"MANE":"Veradermics, Inc.","BK4007":"制药"},"translate_title":"Veradermics脱发数据和资金重新点燃了人们对MANE股票的兴趣","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MANE":1.5},"content_text":"Veradermics (NYSE:MANE) reported positive Phase 2/3 topline results for its oral pattern hair loss candidate VDPHL01, positioning it as a potential first new FDA-approved oral option in this category in almost 30 years. The company also highlighted completion of enrollment in other key clinical studies and recent substantial funding to support ongoing programs. The stock last closed at $107.14, with a 30 day return of 50.1% and a year to date return of 183.8%.  For investors watching NYSE:MANE, the strong move in the share price over the past month and year to date provides a clear backdrop for this clinical update. With a last close of $107.14, the stock has gained 50.1% over the past 30 days and 183.8% year to date, while the 7 day return is down 2.4%, reflecting some recent consolidation after a sharp run. Looking ahead, the focus now shifts to how Veradermics translates these topline results, broader trial progress, and its recent funding into regulatory milestones and potential commercialization plans for VDPHL01. Investors are likely to monitor upcoming clinical readouts and any regulatory interactions closely, given the prospect of a first-in-decades oral treatment for pattern hair loss. Stay updated on the most important news stories for Veradermics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Veradermics. NYSE:MANE 1-Year Stock Price Chart See which insiders are buying and buying and selling Veradermics following this latest news. AdvertisementInvestor Checklist Quick Assessment  ⚖️ Price vs Analyst Target: At US$107.14, Veradermics trades about 15% below the US$126 consensus target range midpoint. ✅ Simply Wall St Valuation: The stock is flagged as trading 71.7% below an estimated fair value, which is a wide discount. ✅ Recent Momentum: A 50.1% 30 day return shows very strong recent momentum into this Phase 2/3 topline readout.  There is only one way to know the right time to buy, sell or hold Veradermics. Head to Simply Wall St's\ncompany report for the latest analysis of Veradermics's Fair Value. Key Considerations  📊 Positive Phase 2/3 topline data for VDPHL01 plus recent funding sharpen the story around a potential first in decades oral treatment for pattern hair loss. 📊 Watch upcoming regulatory updates, further trial readouts and how the share price behaves against the US$120 to US$138 analyst target range. ⚠️ The company currently reports no revenue and has had losses, and the share price has been highly volatile over the past three months.  Dig Deeper For the full picture including more risks and rewards, check out the\ncomplete Veradermics analysis. Alternatively, you can visit the\ncommunity page for Veradermics to see how other investors believe this latest news will impact the company's narrative.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635799146","isCrawlerRequest":true}